<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROPRANOLOL HYDROCHLORIDE- propranolol hydrochloride injection, solution </strong><br>Cardinal Health<br></p></div>
<h1> Propranolol Hydrochloride Injection, USP </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_737b62ef-060a-4b7d-8922-72a48cd95784"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Propranolol hydrochloride is a synthetic beta-adrenergic receptor blocking agent chemically described as (+)-1-(isopropylamino)-3-(1-naphthyloxy)-2-propanol hydrochloride. Its structural formula is:</p>
<div class="Figure"><img alt="Propranolol Hydrochloride Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=87688f92-a620-437d-904a-25c19d4270c8&amp;name=87688f92-a620-437d-904a-25c19d4270c8-01.jpg"></div>
<p>Propranolol hydrochloride is a stable, white to off-white, crystalline solid, which is readily soluble in water and ethanol. Molecular formula: C<span class="Sub">16</span>H<span class="Sub">21</span>NO<span class="Sub">2</span> • HCl. Molecular weight: 295.80. pH range: 2.8 to 4.0.</p>
<p>Propranolol hydrochloride injection, USP is a sterile injectable solution for intravenous administration. Each mL contains propranolol hydrochloride 1 mg, anhydrous citric acid to adjust pH, and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_843cc3c0-3516-44cb-8e7d-b3db052b7ed2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4d359f9-6b83-4884-a717-827309c8fa89"></a><a name="section-2.1"></a><p></p>
<h2>General</h2>
<p class="First">Propranolol is a nonselective beta-adrenergic receptor blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor stimulating agents for available receptor sites. When access to beta-receptor sites is blocked by propranolol, chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately. At doses greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> is uncertain.</p>
</div>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_70e9bb6a-253f-4fcd-88d3-1751ddb101dd"></a><a name="section-2.2"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The effects of propranolol are due to selective blockade of beta-adrenergic receptors, leaving alpha-adrenergic responses intact. There are two well-characterized subtypes of beta receptors (beta <span class="Sub">1</span> and beta<span class="Sub">2</span>); propranolol interacts with both subtypes equally. Beta<span class="Sub">1</span>-adrenergic receptors are found primarily in the heart. Blockade of cardiac beta<span class="Sub">1</span>-adrenergic receptors leads to a decrease in the activity of both normal and ectopic pacemaker cells and a decrease in A-V nodal conduction velocity. All of these actions can contribute to antiarrhythmic activity and control of ventricular rate during <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. Blockade of cardiac beta<span class="Sub">1</span>-adrenergic receptors also decreases the myocardial force of contraction and may provoke cardiac decompensation in patients with minimal cardiac reserve.</p>
<p>Beta<span class="Sub">2</span>-adrenergic receptors are found predominantly in smooth muscle–vascular, bronchial, gastrointestinal and genitourinary. Blockade of these receptors results in constriction. Clinically, propranolol may exacerbate respiratory symptoms in patients with obstructive pulmonary diseases such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span> (see <span class="Bold"><a href="#i4i_contraindications_id_057a9ebd-3d83-4f4a-a2a0-b087bb734a37">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_e2ee063b-3a6d-4426-8578-2daef908a42c">WARNINGS</a></span>).</p>
<p>Propranolol’s beta blocking effects are attributable to its S(-) enantiomer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c21a5f5-523e-4b22-83dc-360e146ae6ed"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics and Drug Metabolism</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18587cc2-23f0-4ee4-a32a-a2ecd9e3eac9"></a><a name="section-2.3.1"></a><p></p>
<h3>Distribution</h3>
<p class="First">Propranolol has a distribution half-life (T<span class="Sub">1/2</span> alpha) of 5 to 10 minutes and a volume of distribution of about 4 to 5 L/kg. Approximately 90% of circulating propranolol is bound to plasma proteins. The binding is enantiomer-selective. The S-isomer is preferentially bound to alpha<span class="Sub">1</span> glycoprotein and the R-isomer is preferentially bound to albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99247c9b-c6e0-480f-827d-c9f4e71955da"></a><a name="section-2.3.2"></a><p></p>
<h3>Metabolism and Elimination</h3>
<p class="First">The elimination half-life (T<span class="Sub">1/2</span> beta) is between 2 and 5.5 hours. Propranolol is extensively metabolized with most metabolites appearing in the urine. The major metabolites include propranolol glucuronide, naphthyloxylactic acid, and glucuronic acid and sulfate conjugates of 4-hydroxy propranolol. Following single-dose intravenous administration, side-chain oxidative products account for approximately 40% of the metabolites, direct conjugation products account for approximately 45 to 50% of metabolites, and ring oxidative products account for approximately 10 to 15% of metabolites. Of these, only the primary ring oxidative product (4-hydroxypropranolol) possesses beta-adrenergic receptor blocking activity.</p>
<p><span class="Italics">In vitro</span> studies have indicated that the aromatic hydroxylation of propranolol is catalyzed mainly by polymorphic CYP2D6. Side-chain oxidation is mediated mainly by CYP1A2 and to some extent by CYP2D6. 4-hydroxy propranolol is a weak inhibitor of CYP2D6.</p>
</div>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_6136ab4a-ffe6-4d22-be44-b071ec08c47a"></a><a name="section-2.4"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">As propranolol concentration increases, so does its beta-blocking effect, as evidenced by a reduction in exercise-induced <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> (n=6 normal volunteers).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9df2bc5-916a-45ad-8fbd-6134054cb883"></a><a name="section-2.5"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c4f9e423-a9f0-4f97-a3f1-1854e958f03f"></a><a name="section-2.5.1"></a><p></p>
<h3>Pediatric</h3>
<p class="First">The pharmacokinetics of propranolol have not been investigated in patients under 18 years of age. Propranolol injection is not recommended for treatment of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d5831ad-ad21-4dbc-b2a4-783fbc669a52"></a><a name="section-2.5.2"></a><p></p>
<h3>Geriatric</h3>
<p class="First">Elevated propranolol plasma concentrations, a longer mean elimination half-life (254 vs. 152 minutes), and decreased systemic clearance (8 vs. 13 mL/kg/min) have been observed in elderly subjects when compared to young subjects. However, the apparent volume of distribution seems to be similar in elderly and young subjects. These findings suggest that dose adjustment of propranolol injection may be required for elderly patients (see <span class="Bold"><a href="#i4i_precautions_id_ee3a2641-18fe-49a0-9b41-cde6083d7d4a">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75716135-3d73-421d-9128-45db2cd46cf9"></a><a name="section-2.5.3"></a><p></p>
<h3>Gender</h3>
<p class="First">Intravenously administered propranolol was evaluated in 5 women and 6 men. When adjusted for weight, there were no gender-related differences in elimination half-life, volume of distribution, protein binding, or systemic clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_db859379-4856-44d1-a193-a8564228255b"></a><a name="section-2.5.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span></h3>
<p class="First">In a study of intravenously administered propranolol, obese subjects had a higher AUC (161 versus 109 hr·mcg/L) and lower total clearance than did non-obese subjects. Propranolol plasma protein binding was similar in both groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5acd539b-0799-47a4-bd2e-e7ee780bd909"></a><a name="section-2.5.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">The pharmacokinetics of propranolol and its metabolites were evaluated in 15 subjects with varying degrees of renal function after propranolol administration via the intravenous and oral routes. When compared with normal subjects, an increase in fecal excretion of propranolol conjugates was observed in patients with increased <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Propranolol was also evaluated in 5 patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>, 6 patients on regular dialysis, and 5 healthy subjects, following a single oral dose of 40 mg of propranolol. The peak plasma concentrations (C<span class="Sub">max</span>) of propranolol in the <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span> group were 2- to 3-fold higher (161 ng/mL) than those observed in the dialysis patients (47 ng/mL) and in the healthy subjects (26 ng/mL). Propranolol plasma clearance was also reduced in the patients with <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">Chronic renal failure</span> has been associated with a decrease in drug metabolism via downregulation of hepatic cytochrome P450 activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f020d381-10a6-4641-ac2e-13b0559d1027"></a><a name="section-2.5.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h3>
<p class="First">Propranolol is extensively metabolized by the liver. In a study conducted in 6 normal subjects and 20 patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>, including <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, 40 mg of R-propranolol was administered intravenously. Compared to normal subjects, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> had decreased clearance of propranolol, increased volume of distribution, decreased protein-binding, and considerable variation in half-life. Caution should be exercised when propranolol is used in this population. Consideration should be given to lowering the dose of intravenous propranolol in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (see <span class="Bold"><a href="#i4i_precautions_id_ee3a2641-18fe-49a0-9b41-cde6083d7d4a">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_38065e2c-a5ec-4873-a5ab-a28c867941f3"></a><a name="section-2.5.7"></a><p></p>
<h3>Thyroid Dysfunction</h3>
<p class="First">No pharmacokinetic changes were observed in hyperthyroid or hypothyroid patients when compared to their corresponding euthyroid state. Dosage adjustment does not seem necessary in either patient population based on pharmacokinetic findings.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b16f4d8-8e90-4780-a4af-e026735d56eb"></a><a name="section-2.6"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e78feeb8-0459-4ae5-8413-2bfdc0da598a"></a><a name="section-2.6.1"></a><p></p>
<h3>Interactions with Substrates, Inhibitors or Inducers of Cytochrome P-450 Enzymes</h3>
<p class="First">Because propranolol’s metabolism involves multiple pathways in the cytochrome P-450 system (CYP2D6, 1A2, 2C19), administration of propranolol with drugs that are metabolized by, or affect the activity (induction or inhibition) of one or more of these pathways may lead to clinically relevant drug interactions (see <span class="Bold"><a href="#i4i_interactions_id_5836137b-0c40-43ca-a0b4-a9b20af3b60d">PRECAUTIONS: Drug Interactions</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_639c7ddf-3ef4-498a-9b3d-5ea0dd159e6e"></a><a name="section-2.6.2"></a><p></p>
<h3>Substrates or Inhibitors of CYP2D6</h3>
<p class="First">Blood levels of propranolol may be increased by administration of propranolol with substrates or inhibitors of CYP2D6, such as amiodarone, cimetidine, delavirdine, fluoxetine, paroxetine, quinidine, and ritonavir. No interactions were observed with either ranitidine or lansoprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0d30696-16c2-4608-8e36-9913e6bff11b"></a><a name="section-2.6.3"></a><p></p>
<h3>Substrates or Inhibitors of CYP1A2</h3>
<p class="First">Blood levels of propranolol may be increased by administration of propranolol with substrates or inhibitors of CYP1A2, such as imipramine, cimetidine, ciprofloxacin, fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b485a4f-4efa-4bb4-b3fa-bc928eb96f06"></a><a name="section-2.6.4"></a><p></p>
<h3>Substrates or Inhibitors of CYP2C19</h3>
<p class="First">Blood levels of propranolol may be increased by administration of propranolol with substrates or inhibitors of CYP2C19, such as fluconazole, cimetidine, fluoxetine, fluvoxamine, teniposide, and tolbutamide. No interaction was observed with omeprazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05b986b8-472f-4de0-aafb-d6c341ff9338"></a><a name="section-2.6.5"></a><p></p>
<h3>Inducers of Hepatic Drug Metabolism</h3>
<p class="First">Blood levels of propranolol may be decreased by administration of propranolol with inducers such as rifampin and ethanol. Cigarette smoking also induces hepatic metabolism and has been shown to increase up to 100% the clearance of propranolol, resulting in decreased plasma concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6bc46cf6-002e-4ef1-85ce-8457c0be8efa"></a><a name="section-2.6.6"></a><p></p>
<h3>Cardiovascular Drugs</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a98f7f1-1063-4ade-bd35-55f2f6baea17"></a><a name="section-2.6.6.1"></a><p></p>
<h4><span class="Bold">Antiarrhythmics</span></h4>
<p class="First">The AUC of propafenone is increased by more than 200% with co-administration of propranolol.</p>
<p>The metabolism of propranolol is reduced by co-administration of quinidine, leading to a 2- to 3-fold increased blood concentrations and greater beta-blockade.</p>
<p>The metabolism of lidocaine is inhibited by co-administration of propranolol, resulting in a 25% increase in lidocaine concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3958a8b8-62e1-439a-a662-ecc11ec89a0f"></a><a name="section-2.6.6.2"></a><p></p>
<h4><span class="Bold">Calcium Channel Blockers</span></h4>
<p class="First">The mean C<span class="Sub">max</span> and AUC of propranolol are increased respectively, by 50% and 30% by co-administration of nisoldipine and by 80% and 47%, by co-administration of nicardipine.</p>
<p>The mean values of C<span class="Sub">max</span> and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.</p>
<p>Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4d620a7-6bff-412a-86c8-d88778254934"></a><a name="section-2.6.7"></a><p></p>
<h3>Non-Cardiovascular Drugs</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b74c3082-3a47-4754-bad9-b736290622c7"></a><a name="section-2.6.7.1"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Drugs</span></h4>
<p class="First">Administration of zolmitriptan or rizatriptan with propranolol resulted in increased concentrations of zolmitriptan (AUC increased by 56% and C<span class="Sub">max</span> by 37%) or rizatriptan (the AUC and C<span class="Sub">max</span> were increased by 67% and 75%, respectively).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5f587b4-58a9-4cc7-9bf4-de2e27818a7f"></a><a name="section-2.6.7.2"></a><p></p>
<h4><span class="Bold">Theophylline</span></h4>
<p class="First">Co-administration of theophylline with propranolol decreases theophylline clearance by 33% to 52%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e10c7268-0459-49c7-b994-66d4e85ba043"></a><a name="section-2.6.7.3"></a><p></p>
<h4><span class="Bold">Benzodiazepines</span></h4>
<p class="First">Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.</p>
<p>The pharmacokinetics of oxazepam, triazolam, lorazepam, and alprazolam are not affected by co-administration of propranolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e995e1a-d8f6-4b5a-b4cb-fcf13859c870"></a><a name="section-2.6.7.4"></a><p></p>
<h4><span class="Bold">Neuroleptic Drugs</span></h4>
<p class="First">Co-administration of propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 50% to 370% and increased thioridazine metabolites concentrations ranging from 33% to 210%.</p>
<p>Co-administration of chlorpromazine with propranolol resulted in increased plasma levels of both drugs (70% increase in propranolol concentrations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0696fa30-12b2-4211-aa58-e21d7a97ca7e"></a><a name="section-2.6.7.5"></a><p></p>
<h4><span class="Bold">Anti-<span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Drugs</span></h4>
<p class="First">Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol concentrations by about 40%. Co-administration with aluminum hydroxide gel (1200 mg) resulted in a 50% decrease in propranolol concentrations.</p>
<p>Co-administration of metoclopramide with propranolol did not have a significant effect on propranolol’s pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d54ae571-290c-4301-84b0-01f63e737f10"></a><a name="section-2.6.7.6"></a><p></p>
<h4><span class="Bold">Lipid Lowering Drugs</span></h4>
<p class="First">Co-administration of cholesteramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.</p>
<p>Co-administration of propranolol with lovastatin or pravastatin decreased 20% to 25% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fff8de31-c77a-4319-a215-97723720bc04"></a><a name="section-2.6.7.7"></a><p></p>
<h4><span class="Bold">Warfarin</span></h4>
<p class="First">Concomitant administration of propranolol and warfarin has been shown to increase warfarin bioavailability and increase <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_a30b0ed6-7318-49d3-97f9-293a9bef6e74"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">In a series of 225 patients with supraventricular (n=145), ventricular (n=69), or both (n=11) arrythmias resistant to digitalis, intravenous propranolol hydrochloride was administered in single doses, averaging 1 to 5 mg. Approximately one-quarter of the patients with supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (generally those with sinus or <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span>) reverted to normal sinus rhythm. About one-half had symptoms ameliorated either by a decrease in ventricular rate or an attenuation of frequency or severity of paroxysmal attacks.</p>
<p>Approximately one-half of patients with <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> (generally those with frequent PVCs) reverted to normal sinus rhythm or responded with a reduction in ventricular rate.</p>
<p>Similar findings were seen in a series of 25 Bantu patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (n=16), <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span> (n=5), and multifocal <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span> (n=9).</p>
<p>In another series, 7 of 8 patients with digitalis-related <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span> had ventricular rate decreases after intravenous propranolol. Similarly limited clinical experience has shown that intravenous propranolol will slow the ventricular rate in patients with Wolff-Parkinson-White syndrome or with <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> associated with <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>.</p>
<p>Onset of activity is usually within five minutes.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_fdb6c3d8-37a4-4d34-ab6c-cd99f50ccfa7"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_800019b6-4ed8-4abf-83a0-3699ff6e3d12"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span></h2>
<p class="First">Intravenous administration is usually reserved for life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> or those occurring under anesthesia.</p>
<ol>
<li>Supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span><br>Intravenous propranolol is indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, including Wolff-Parkinson-White syndrome and <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span>, to decrease ventricular rate. Use in patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">Ventricular tachycardias</span><br>With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See <span class="Bold"><a href="#i4i_dosage_admin_id_c299c968-bc8c-4541-8fd1-f62551bb07d0">DOSAGE AND ADMINISTRATION</a></span>). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> do not respond to propranolol as predictably as do the supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. Intravenous propranolol is indicated for the treatment of persistent premature <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span> that impair the well-being of the patient and do not respond to conventional measures.</li>
<li><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmias</span> of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span><br>Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. Severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> may occur. (See <span class="Bold"><a href="#i4i_overdosage_id_a89e044f-b877-499f-a43e-cf21a9b3d0ae">OVERDOSAGE</a></span>).</li>
<li>Resistant <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span> due to excessive catecholamine action during anesthesia<br>Intravenous propranolol is indicated to abolish <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span> due to excessive catecholamine action during anesthesia when other measures fail. These <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Therefore, when propranolol is used to treat <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See <span class="Bold"><a href="#i4i_warnings_id_e2ee063b-3a6d-4426-8578-2daef908a42c">WARNINGS</a></span>).</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_057a9ebd-3d83-4f4a-a2a0-b087bb734a37"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Propranolol is contraindicated in 1) <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; 2) <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span> and greater than first-degree block; 3) bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; and 4) in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to propranolol hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e2ee063b-3a6d-4426-8578-2daef908a42c"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fdc5965e-19be-4815-9bd7-88420ac8af84"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation may be a vital component supporting circulatory function in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and its inhibition by beta blockade may precipitate more severe failure. Although beta-blockers should be avoided in overt <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, some have been shown to be highly beneficial when used with close follow-up in patients with a history of failure who are well compensated and are receiving additional therapies, including diuretics as needed. Beta-adrenergic blocking agents do not abolish the inotropic action of digitalis on heart muscle.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58dc3b0d-1bae-4260-bc16-d79c67164eeb"></a><a name="section-6.2"></a><p></p>
<h2>Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">Chronic Bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">Emphysema</span>)</h2>
<p class="First">In general, patients with bronchospastic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> should not receive beta blockers. Propranolol should be administered with caution in this setting since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta-receptors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_877a6498-d875-42e6-b654-e5ed00e6dd4d"></a><a name="section-6.3"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">The necessity or desirability of withdrawal of beta-blocking therapy prior to major surgery is controversial. It should be noted, however, that the impaired ability of the heart to respond to reflex adrenergic stimuli in propranolol-treated patients might augment the risks of general anesthesia and surgical procedures.</p>
<p>Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. However, such patients may be subject to protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b3e2ab8-00f0-407e-9f0d-a168935ae617"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Beta-adrenergic blockade may prevent the appearance of certain premonitory signs and symptoms (pulse rate and pressure changes) of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, especially in labile insulin-dependent diabetics. In these patients, it may be more difficult to adjust the dosage of insulin.</p>
<p>Propranolol therapy, particularly in infants and children, diabetic or not, has been associated with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> especially during fasting, as in preparation for surgery. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> has been reported after prolonged physical exertion and in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5290c94-a40b-4a4e-915e-a6b30ba0c619"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blockade may mask certain clinical signs of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Therefore, abrupt withdrawal of propranolol may be followed by an exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, including <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>. Propranolol may change thyroid-function tests, increasing T<span class="Sub">4</span> and reverse T<span class="Sub">3</span>, and decreasing T<span class="Sub">3</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_36c1ab55-ee82-4dbe-a408-7c20ceee5a24"></a><a name="section-6.6"></a><p></p>
<h2>Wolff-Parkinson-White Syndrome</h2>
<p class="First">Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> requiring treatment with a pacemaker. In one case this resulted after an initial 5 mg dose of intravenous propranolol.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_ee3a2641-18fe-49a0-9b41-cde6083d7d4a"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_762288db-0b1f-4996-b7d9-6cf694b95d41"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol is not indicated for the treatment of hypertensive emergencies.</p>
<p>Beta-adrenergic receptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol might interfere with the <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> screening test. Withdrawal may lead to a return of elevated intraocular pressure.</p>
<p>Risk of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>. While taking beta blockers, patients with a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_40b35383-4341-4d83-b950-4b491e3336df"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina Pectoris</span></h3>
<p class="First">There have been reports of exacerbation of angina and, in some cases, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, following abrupt discontinuance of propranolol therapy. Therefore, when discontinuance of propranolol is planned, the dosage should be gradually reduced over at least a few weeks, and the patient should be cautioned against interruption or cessation of therapy without a physician’s advice. If propranolol therapy is interrupted and exacerbation of angina occurs, it is usually advisable to reinstitute propranolol therapy and take other measures appropriate for the management of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. Since <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> may be unrecognized, it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease who are given propranolol for other indications.</p>
</div>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_2471a4a5-8e72-4b3b-9ae6-3e6f5e2c84c3"></a><a name="section-7.2"></a><p></p>
<h2>Clinical Laboratory Tests</h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, use of propranolol has been associated with elevated levels of serum potassium, serum transaminases and alkaline phosphatase. In severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, the use of propranolol has been associated with increases in Blood Urea Nitrogen.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_5836137b-0c40-43ca-a0b4-a9b20af3b60d"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Caution should be exercised when propranolol is administered with drugs that have an effect on CYP2D6, 1A2, or 2C19 metabolic pathways. Co-administration of such drugs with propranolol may lead to clinically relevant drug interactions and changes in its efficacy and/or toxicity (see <span class="Bold"><a href="#i4i_section_id_5b16f4d8-8e90-4780-a4af-e026735d56eb">CLINICAL PHARMACOLOGY: Drug Interactions</a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_71288b05-a474-4c64-9e9e-8629b30af44c"></a><a name="section-7.3.1"></a><p></p>
<h3>Cardiovascular Drugs</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1baf6221-6360-47ce-9a8e-7e8d7769fd4b"></a><a name="section-7.3.1.1"></a><p></p>
<h4><span class="Bold">Antiarrhythmics</span></h4>
<p class="First">Propafenone has negative inotropic and beta-blocking properties that can be additive to those of propranolol.</p>
<p>Quinidine increases the concentration of propranolol and produces a greater degree of clinical beta-blockade and may cause <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
<p>Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects and has been associated with severe <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> when administered with propranolol.</p>
<p>Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with propranolol.</p>
<p>The clearance of lidocaine is reduced when administered with propranolol. Lidocaine toxicity has been reported following coadministration with propranolol.</p>
<p>Caution should be exercised when administering propranolol with drugs that slow A-V nodal conduction, e.g. digitalis, lidocaine and calcium channel blockers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8ff90fd-2d9e-41f2-965a-e2096a663d6e"></a><a name="section-7.3.1.2"></a><p></p>
<h4><span class="Bold">Calcium Channel Blockers</span></h4>
<p class="First">Caution should be exercised when patients receiving a beta-blocker are administered a calcium-channel-blocking drug with negative inotropic and/or chronotropic effects. Both agents may depress myocardial contractility or atrioventricular conduction.</p>
<p>There have been reports of significant <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> with concurrent use of verapamil and beta-blockers.</p>
<p>Co-administration of propranolol and diltiazem in patients with cardiac disease has been associated with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, high degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc378f08-289b-487f-9095-0d0d2ee5e55f"></a><a name="section-7.3.1.3"></a><p></p>
<h4><span class="Bold">ACE Inhibitors</span></h4>
<p class="First">When combined with beta-blockers, ACE inhibitors can cause <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, particularly in the setting of <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>.</p>
<p>ACE inhibitors have been reported to increase <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">bronchial hyperreactivity</span> when administered with propranolol.</p>
<p>The antihypertensive effects of clonidine may be antagonized by beta-blockers. Propranolol should be administered cautiously to patients withdrawing from clonidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb11a87d-0e39-44d8-b168-04e7d74c91ed"></a><a name="section-7.3.1.4"></a><p></p>
<h4><span class="Bold">Alpha-blockers</span></h4>
<p class="First">Prazosin has been associated with prolongation of first dose <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the presence of beta-blockers.</p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span> has been reported in patients taking both beta-blockers and terazosin or doxazosin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7eb5b4ea-24af-4940-a436-b8b65f12f9d0"></a><a name="section-7.3.1.5"></a><p></p>
<h4><span class="Bold">Reserpine</span></h4>
<p class="First">Patients receiving catecholamine-depleting drugs, such as reserpine, with propranolol should be closely observed for excess reduction of resting sympathetic nervous activity, which may result in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, syncopal attacks, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. Administration of reserpine with propranolol may also potentiate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c203493a-e913-4584-a67a-f32de16376e9"></a><a name="section-7.3.1.6"></a><p></p>
<h4><span class="Bold">Inotropic Agents</span></h4>
<p class="First">Patients on long-term therapy with propranolol may experience <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> if administered epinephrine as a consequence of unopposed alpha-receptor stimulation. Epinephrine is therefore not indicated in the treatment of propranolol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (see <span class="Bold"><a href="#i4i_overdosage_id_a89e044f-b877-499f-a43e-cf21a9b3d0ae">OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c740b010-6c3b-4c50-886f-4f90ec97e7ab"></a><a name="section-7.3.1.7"></a><p></p>
<h4>
<span class="Bold">Isoproterenol and </span><span class="Bold">Dobutamine</span>
</h4>
<p class="First">Propranolol is a competitive inhibitor of beta-receptor agonists, and its effects can be reversed by administration of such agents, e.g., dobutamine or isoproterenol. Also, propranolol may reduce sensitivity to dobutamine stress echocardiography in patients undergoing evaluation for <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_938a8fd5-6fc8-4909-9c80-ecb2a8429f8b"></a><a name="section-7.3.2"></a><p></p>
<h3>Non-Cardiovascular Drugs</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b47a4360-3d75-4ac9-9c12-f7655af8e8e0"></a><a name="section-7.3.2.1"></a><p></p>
<h4><span class="Bold">Non-Steroidal Anti-Inflammatory Drugs</span></h4>
<p class="First">Nonsteroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-adrenoreceptor blocking agents.</p>
<p>Administration of indomethacin with propranolol may reduce the efficacy of propranolol in reducing blood pressure and heart rate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d38dfc8-bc4a-4b65-8d9c-9125a01b67d7"></a><a name="section-7.3.2.2"></a><p></p>
<h4><span class="Bold">Antidepressants</span></h4>
<p class="First">The hypotensive effects of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers by interfering with the beta blocking activity of propranolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4bca025-b931-4ac4-8835-ac5b8d2dc3ad"></a><a name="section-7.3.2.3"></a><p></p>
<h4><span class="Bold">Anesthetic Agents</span></h4>
<p class="First">Methoxyflurane and trichloroethylene may depress myocardial contractility when administered with propranolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbcf413a-acea-4937-bc81-6c5013900c2f"></a><a name="section-7.3.2.4"></a><p></p>
<h4><span class="Bold">Warfarin</span></h4>
<p class="First">Administration of propranolol with warfarin increases the concentration of warfarin. Therefore, the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_633f589f-b2fc-438f-9449-00caccedfea1"></a><a name="section-7.3.2.5"></a><p></p>
<h4><span class="Bold">Neuroleptic Drugs</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> have been reported with the concomitant use of propranolol and haloperidol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_561c7c6e-1e34-43ae-a23b-896f407a1d2a"></a><a name="section-7.3.2.6"></a><p></p>
<h4><span class="Bold">Thyroxine</span></h4>
<p class="First">Thyroxine may result in a lower than expected T<span class="Sub">3</span> concentration when used concomitantly with propranolol.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d395a18c-8646-4102-9799-61dba3e08870"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In dietary administration studies in which mice and rats were treated with propranolol hydrochloride for up to 18 months at doses of up to 150 mg/kg/day, there was no evidence of drug-related tumorigenesis. On a body surface area basis, this dose in the mouse and rat is, respectively, about equal to and about twice the maximum recommended human oral daily dose (MRHD) of 640 mg propranolol hydrochloride. In a study in which both male and female rats were exposed to propranolol hydrochloride in their diets at concentrations of up to 0.05% (about 50 mg/kg body weight and less than the MRHD), from 60 days prior to mating and throughout pregnancy and lactation for two generations, there were no effects on fertility. Based on differing results from Ames Tests performed by different laboratories, there is equivocal evidence for a genotoxic effect of propranolol hydrochloride in bacteria ( <span class="Italics">S</span><span class="Italics">. </span><span class="Italics">typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA 1538).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_3aca7a53-0406-4e7b-b860-87243c20c4b9"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_91a1596b-fb5b-4fe0-a358-2b57d867f861"></a><a name="section-7.5.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">In a series of reproductive and developmental toxicology studies, propranolol hydrochloride was given to rats by gavage or in the diet throughout pregnancy and lactation. At doses of 150 mg/kg/day, but not at doses of 80 mg/kg/day (equivalent to the MRHD on a body surface area basis), treatment was associated with embryotoxicity (reduced litter size and increased resorption rates) as well as neonatal toxicity (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>). Propranolol hydrochloride also was administered (in the feed) to rabbits (throughout pregnancy and lactation) at doses as high as 150 mg/kg/day (about 5 times the maximum recommended human oral daily dose). No evidence of embryo or neonatal toxicity was noted.</p>
<p>There are no adequate and well-controlled studies in pregnant women. <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">Intrauterine growth retardation</span> has been reported for neonates whose mothers received propranolol hydrochloride during pregnancy. Neonates whose mothers received propranolol hydrochloride at parturition have exhibited <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Adequate facilities for monitoring such infants at birth should be available. Propranolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_1db8d106-78d2-4c91-98b7-7f8fccd55ab1"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Propranolol is excreted in human milk. Caution should be exercised when propranolol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ee57a1be-156f-4444-8d68-4fe916501b2c"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of propranolol in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_83de4cd7-b923-4f29-9207-2aa60695cd45"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of intravenous propranolol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly subjects have decreased clearance and a longer mean elimination half-life. These findings suggest that dose adjustment of propranolol injection may be required for elderly patients (see <span class="Bold"><a href="#i4i_section_id_5d5831ad-ad21-4dbc-b2a4-783fbc669a52">CLINICAL PHARMACOLOGY: Special Populations: </a><span class="Italics"><a href="#i4i_section_id_5d5831ad-ad21-4dbc-b2a4-783fbc669a52">Geriatric</a></span></span>). In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of the decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5ab61b22-8b38-446d-b823-8a69acb6120a"></a><a name="section-7.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Propranolol is extensively metabolized by the liver. Compared to normal subjects, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> have decreased clearance of propranolol, increased volume of distribution, decreased protein-binding and considerable variation in half life. Consideration should be given to lowering the dose of intravenously administered propranolol in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f4446cda-f811-491f-bd21-4194fa13e7b8"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In a series of 225 patients, there were 6 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (see <span class="Bold"><a href="#i4i_clinical_studies_id_a30b0ed6-7318-49d3-97f9-293a9bef6e74">CLINICAL STUDIES</a></span>). Cardiovascular events (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>) were the most common. The only other event reported by more than one patient was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<p>Other adverse events for intravenous propranolol, reported during post-marketing surveillance include <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and cutaneous <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>.</p>
<p>The following adverse events have been reported with use of formulations of sustained- or immediate-release oral propranolol and may be expected with intravenous propranolol.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0dec2fa-507c-4f93-8044-aa866a525fbb"></a><a name="section-8.1"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>; <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; intensification of <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of hands; <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, usually of the Raynaud type.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_444f0d2a-91cd-4205-aba8-607b018edff8"></a><a name="section-8.2"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First">Light-headedness; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> manifested by <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span>; an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate-release formulations, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, and <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">vivid dreams</span> appear dose related.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd659efe-7110-4a1c-9f8c-753fe4fd25c4"></a><a name="section-8.3"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, abdominal cramping, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_07f4ecb5-f56a-4cee-8afd-c7f8a1f842da"></a><a name="section-8.4"></a><p></p>
<h2>Allergic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>; <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f57e13de-3d0c-4a82-8aee-c718a2552fcc"></a><a name="section-8.5"></a><p></p>
<h2>Respiratory</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d7a5c09-4f33-47da-b3f1-b16632ce5f9d"></a><a name="section-8.6"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57314b6b-37b7-4ee4-a16d-c072aea0ee67"></a><a name="section-8.7"></a><p></p>
<h2>Autoimmune</h2>
<p class="First">In extremely rare instances, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_634b0500-97b4-4dfe-bf3f-829c909bacb6"></a><a name="section-8.8"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, LE-like reactions, psoriaform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, male <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and Peyronie’s disease have been reported rarely. Oculomucocutaneous reactions involving the skin, serous membranes and conjunctivae reported for a beta-blocker (practolol) have not been associated with propranolol.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a89e044f-b877-499f-a43e-cf21a9b3d0ae"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Propranolol is not significantly dialyzable. In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or exaggerated response, the following measures should be employed:</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> have been reported following propranolol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and should be treated appropriately. Glucagon can exert potent inotropic and chronotropic effects and may be particularly useful for the treatment of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or depressed myocardial function after a propranolol <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Glucagon should be administered as 50 to 150 mcg/kg intravenously followed by continuous drip of 1 to 5 mg/hour for positive chronotropic effect. Isoproterenol, dopamine, or phosphodiesterase inhibitors may also be useful. Epinephrine, however, may provoke <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> can be treated with atropine or isoproterenol. Serious <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> may require temporary cardiac pacing.</p>
<p>The electrocardiogram, pulse, blood pressure, neurobehavioral status and intake and output balance must be monitored. Isoproterenol and aminophylline may be useful for <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_c299c968-bc8c-4541-8fd1-f62551bb07d0"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>The usual dose is 1 to 3 mg administered under careful monitoring, such as electrocardiography and central venous pressure. The rate of administration should not exceed 1 mg (1 mL) per minute to diminish the possibility of lowering blood pressure and causing cardiac standstill. Sufficient time should be allowed for the drug to reach the site of action even when a slow circulation is present. If necessary, a second dose may be given after two minutes. Thereafter, additional drug should not be given in less than four hours. Additional propranolol hydrochloride should not be given when the desired alteration in rate or rhythm is achieved.</p>
<p>Transfer to oral therapy as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_8441a828-55c3-4873-b9cd-0f3fe7f6a42d"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Propranolol hydrochloride injection, USP contains 1 mg propranolol hydrochloride, anhydrous citric acid to adjust pH, and water for injection; and is supplied as follows:</p>
<p><span class="Bold">1 mg/mL:</span></p>
<p>NDC 0781-3777-95 – 1 mL fill in 2 mL vials; boxes of 10</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_faf208bf-503c-44ef-822f-8fbd4ae251ff"></a><a name="section-11.1"></a><p></p>
<p class="First">Store at 20°-25°C (68°-77°F) (see USP Controlled Room Temperature).</p>
<p>Protect from freezing and excessive heat.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c4043f3-8307-43f5-ac45-1a485d062313"></a><a name="section-11.2"></a><p></p>
<p class="First">10-2008M</p>
<p>D1006645</p>
<p>Manufactured in Canada by Sandoz Canada Inc. for</p>
<p>Sandoz Inc., Princeton, NJ 08540</p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>IA67011111</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f38c1b7a-30b6-4595-865a-b3e75cab9f07"></a><a name="section-12"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First">Propranolol Hydrochloride Injection, USP</p>
<p>1 mg/mL</p>
<p>1 x 1 mL Single Use Vial</p>
<div class="Figure"><img alt="Bag" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=87688f92-a620-437d-904a-25c19d4270c8&amp;name=87688f92-a620-437d-904a-25c19d4270c8-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROPRANOLOL HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">propranolol hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-5445(NDC:0781-3777)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROPRANOLOL HYDROCHLORIDE</strong> (PROPRANOLOL) </td>
<td class="formItem">PROPRANOLOL HYDROCHLORIDE</td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-5445-8</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA076400</td>
<td class="formItem">02/26/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-5445)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>87688f92-a620-437d-904a-25c19d4270c8</div>
<div>Set id: 87688f92-a620-437d-904a-25c19d4270c8</div>
<div>Version: 1</div>
<div>Effective Time: 20130419</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
